Shire Mexico – Dr. Raul Vivar, Head of Mexico / Central America and…
The general manager in charge of Mexico, Central America and the Caribbean is on board with the corporate mission of doubling Shire’s product sales to USD 10 billion by 2020…
As one of the world’s leading specialty biopharmaceutical companies, Shire has emerged as a company fully focused on a single purpose: to enable people with life-altering conditions to lead better lives. Today Shire provides treatments in the areas of Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine. The company has a portfolio of specialist therapies marketed in over 50 countries worldwide and offices in 29 countries. The company has been present in Mexico since 2008 focusing on lysosomal storage diseases therapies. In the near future the company plans to provide a therapeutic option to patients with hereditary angioedema and start its neuroscience business unit with a product indicated for ADHD (attention deficit hyperactivity disorder).
Address:
Shire Pharmaceuticals Mexico S.A. de C.V Av. Paseo de los Tamarindos 90, Torre 1, Piso 7 Col. Bosques de las Lomas, Del. Cuajimalpa C.P. 05120, México DF MEXICO Tel: +52 (55) 5081 0120 Website: www.shire.com.mx
The general manager in charge of Mexico, Central America and the Caribbean is on board with the corporate mission of doubling Shire’s product sales to USD 10 billion by 2020…
Ricardo Amtmann, President at Laboratorios Sanfer, explains how they have grown their business by 100 percent throughout the last three years and showcases the added value of Sanfer to patients…
Patricia López, general manager at seca Mexico, showcases the added value of seca’s product portfolio and explains that interconnectivity should be medical devices’ path of development; generating benefits for patients,…
Patrick Troop, CEO at Pharma Tycsa, explains the company’s unique business approach in Mexico developing “clinical pharmacies” model to address chronic diseases treatment in the points of care and the…
Victor Manuel Fernández Navarro, CEO at Vicma, explains how strategically important is to have a healthy business model in the distribution industry through sustainable collection period, attractive profit margins and…
Dr. Marco A. Martinez Rios, General Director of the National Institute of Cardiology in Mexico elaborates on the institution’s rich history in Mexico and its contributions to cardiology through research,…
Andrés Matesanz, general manager at DCS Pharma Mexico, explains how the merger between Dolder and Chemswiss has enlarged the capabilities and the offering of the company in Mexico and showcases…
José Alberto Peña, managing director at Marzam Mexico, showcases the benefits that distributors can offer to the healthcare and life science sector as well as Marzam’s strategy to overcome the…
Carlos Pérez Muguía, CEO at NYCE, showcases the increasing added value brought by this leading Cofepris’ authorized third party (ATP) to the healthcare industry, the future objectives of the company…
Alan Smithers, CEO at IFA Celtics, highlights the obesity as a national healthcare challenge and explains the company’s strategy to enlarge its capabilities to cope with the increasing needs of…
Salomon Rayek, CEO at Sinbiotik, explains how the company managed to adapt its business model to the industry trends and showcases the added value of Sinbiotik when offering high quality,…
Due to economic necessity, the Mexican government is attempting to slash annual spending; an act that could have serious consequences on the country’s ability to provide its citizens with healthcare.…
Francisco Rodriguez, general manager Mexico and Latin America at Mundipharma, provides an overview of the customized market approach that has allowed the company to establish itself as the partner of…
See our Cookie Privacy Policy Here
